Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Outstanding (Weighted Average) (2020 - 2025)

Tarsus Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $41.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $41.8 million for Q4 2025, up 11.11% from a year ago — trailing twelve months through Dec 2025 was $41.8 million (up 11.11% YoY), and the annual figure for FY2025 was $41.8 million, up 11.11%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $41.8 million at Tarsus Pharmaceuticals, down from $42.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TARS hit a ceiling of $42.6 million in Q3 2025 and a floor of $20.3 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $27.4 million (2023), compared with a mean of $29.9 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 671.31% in 2021 and later grew 1.84% in 2022.
  • Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $20.6 million in 2021, then rose by 19.78% to $24.6 million in 2022, then increased by 19.35% to $29.4 million in 2023, then grew by 27.98% to $37.6 million in 2024, then grew by 11.11% to $41.8 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $41.8 million (Q4 2025), $42.6 million (Q3 2025), and $40.9 million (Q2 2025) per Business Quant data.